Geron Corporation (GERN): Price and Financial Metrics

Geron Corporation (GERN): $2.07

0.02 (-0.96%)

POWR Rating

Component Grades








Add GERN to Watchlist
Sign Up

Industry: Biotech




#346 of 347

in industry

GERN Price/Volume Stats

Current price $2.07 52-week high $3.84
Prev. close $2.09 52-week low $1.68
Day low $2.02 Volume 3,457,200
Day high $2.10 Avg. volume 6,553,975
50-day MA $1.89 Dividend yield N/A
200-day MA $2.53 Market Cap 1.12B

GERN Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where GERN ranks best; there it ranks ahead of 35.53% of US stocks.
  • GERN's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • GERN's current lowest rank is in the Stability metric (where it is better than 6.48% of US stocks).

GERN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for GERN is 0 -- better than just 8.38% of US stocks.
  • With a price/sales ratio of 3,409.14, GERON CORP has a higher such ratio than 99.85% of stocks in our set.
  • As for revenue growth, note that GERN's revenue has grown -79.32% over the past 12 months; that beats the revenue growth of merely 2.25% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GERON CORP are GSIT, BCDA, VTGN, INO, and CBAY.
  • Visit GERN's SEC page to see the company's official filings. To visit the company's web site, go to

GERN Valuation Summary

  • GERN's price/sales ratio is 3443.5; this is 90518.42% higher than that of the median Healthcare stock.
  • Over the past 243 months, GERN's price/sales ratio has gone up 3089.1.

Below are key valuation metrics over time for GERN.

Stock Date P/S P/B P/E EV/EBIT
GERN 2023-11-20 3443.5 3.8 -6.2 -6.7
GERN 2023-11-17 3374.8 3.7 -6.1 -6.6
GERN 2023-11-16 3203.5 3.5 -5.8 -6.2
GERN 2023-11-15 3323.3 3.6 -6.0 -6.5
GERN 2023-11-14 3272.2 3.6 -5.9 -6.4
GERN 2023-11-13 3083.6 3.4 -5.6 -6.0

GERN Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at -168.47%.
  • Its year over year revenue growth rate is now at 307.99%.
  • The 2 year revenue growth rate now stands at 203.08%.
Over the past 33 months, GERN's revenue has gone up $1,073,000.

The table below shows GERN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.533 -114.366 -131.283
2022-06-30 1.345 -107.624 -116.929
2022-03-31 1.379 -96.796 -118.386
2021-12-31 1.393 -95.556 -116.112
2021-09-30 0.403 -86.002 -107.882
2021-06-30 0.402 -78.611 -100.836

GERN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GERN has a Quality Grade of C, ranking ahead of 52.18% of graded US stocks.
  • GERN's asset turnover comes in at 0.002 -- ranking 426th of 682 Pharmaceutical Products stocks.
  • NSTG, NEOG, and CLVS are the stocks whose asset turnover ratios are most correlated with GERN.

The table below shows GERN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.002 1 -0.424
2021-03-31 0.001 1 -0.352
2020-12-31 0.001 1 -0.350
2020-09-30 0.002 1 -0.448
2020-06-30 0.002 1 -0.503
2020-03-31 0.003 1 -0.589

GERN Price Target

For more insight on analysts targets of GERN, see our GERN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.20 Average Broker Recommendation 1.38 (Strong Buy)

Geron Corporation (GERN) Company Bio

Geron Corporation focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

GERN Latest News Stream

Event/Time News Detail
Loading, please wait...

GERN Latest Social Stream

Loading social stream, please wait...

View Full GERN Social Stream

Latest GERN News From Around the Web

Below are the latest news stories about GERON CORP that investors may wish to consider to help them evaluate GERN as an investment opportunity.

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

FOSTER CITY, Calif., December 06, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial investigating the Company’s first-in-class telomerase inhibitor, imetelstat, versus best available therapy (BAT) in patients with relapsed/refractory myelofibrosis (MF).

Yahoo | December 6, 2023

Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

FOSTER CITY, Calif., December 04, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs). The publication is available online and will be available in print at a later date.

Yahoo | December 4, 2023

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

FOSTER CITY, Calif., November 28, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a history of expertise in financial and corporate strategy, as well as business development, in companies with which he has been affiliated at both an operational and board leve

Yahoo | November 28, 2023

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., November 16, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 438,950 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Yahoo | November 16, 2023

Geron to Participate at Upcoming Investor Conferences in November

FOSTER CITY, Calif., November 07, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences:

Yahoo | November 7, 2023

Read More 'GERN' Stories Here

GERN Price Returns

1-mo 18.29%
3-mo -15.51%
6-mo -38.94%
1-year -9.21%
3-year 20.35%
5-year 46.81%
YTD -14.46%
2022 98.36%
2021 -23.27%
2020 16.91%
2019 36.00%
2018 -44.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!